INTS · Intensity Therapeutics, Inc. · Investor Relations
$3.07
-0.01 (-0.32%)
At close · Nov 16
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Going-concern doubt
— flagged Nov 5, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As of September 30, 2026, our cash and cash equivalents were approximately $8.5 million. Based on our balances in cash and cash equivalents, our ability to continue our operations is dependent on obtaining additional capital, which is not within our control. As a result, we believe there is substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Nov 5, 2026
Market Cap
$10.13M
Shares
3.30M
Volume · Nov 16
4555
Avg daily vol (3M)
22.42K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Upcoming events
| Date | Event | Type |
|---|---|---|
| 2026-12-31 00:00 UTC | 2026 Annual Meeting of Stockholders | Shareholder meeting |
| 2026-12-31 00:00 UTC | H.C. Wainwright 28th Annual Global Investment Conference | Conference |
| 2026-12-31 00:00 UTC | Second Quarter 2026 Financial Results Conference Call | Earnings call |
Recent news
Past events
| Date | Event | Type |
|---|---|---|
| 2026-11-05 | Third Quarter 2026 Financial Results Conference Call | Earnings call |
| 2026-10-23 | 2026 European Society of Medical Oncology (ESMO) Meeting | Event |
| 2026-09-11 | H.C. Wainwright 28th Annual Global Investment Conference | Conference |
| 2026-08-11 | Second Quarter 2026 Financial Results Conference Call | Earnings call |
| 2026-06-16 | 2026 Annual Meeting of Stockholders | Shareholder meeting |
Key facts
CIK
1567264
CUSIP
45828J202
13F (30d)
14 filings
14 filers
Visit website
Investor relations